Quisinostat (dihydrochloride)

• UNSPSC Description:

  Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally available, potent pan-HDAC inhibitor with IC50s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity[1].

• Target Antigen:

  Apoptosis; Autophagy; HDAC

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/quisinostat-dihydrochloride.html

• Solubility:

  DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 70°C)

• Smiles:

  [H]Cl.O=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO.[H]Cl

• Molecular Weight:

  467.39

• References & Citations:

  [1]Arts J, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 2

• CAS Number:

  875320-31-3